[1] Gordon CE, Balk EM,Francis JM. Summary of the 2018 Kidney Disease Improving Global Outcomes (KDIGO) Guideline on hepatitis C in chronic kidney disease.Semin Dial,2019,32:187-195.
[2] Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol,2017,112:18-35.
[3] AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis,2018,67:1477-1492.
[4] Jiang Y, Huang E, Mehrnia A, et al. Can aminotransferase-to-platelet ratio index and other non-invasive markers effectively reduce liver biopsies for renal transplant evaluation of hepatitis C virus-positive patients? Nephrol Dial Transpl, 2014,29:1247-1252.
[5] Liu CH, Liang CC, Huang KW, et al. Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol, 2011,6:1057-1065.
[6] Paramesh AS, Davis JY, Mallikarjun C, et al. Kidney transplantation alone in ESRD patients with hepatitis C cirrhosis. Transplantation,2012,94:250-254.
[7] Lens S, Alvarado-Tapias E, Marino Z, et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology,2017,153:1273-1283 e1271.
[8] Lawitz E, Landis C, Maliakkal B, et al. Safety and efficacy of treatment with once-daily Ledipasvir/Sofosbuvir (90/400 mg) for 12 weeks in genotype 1 HCV-infected patients with severe renal impairment. Hepatology,2017,66:A1952. |
